Novartis AG
DUS:NOT
Novartis AG
DUS:NOT
Price:
133.58
EUR
-0.64%
Market Cap:
€274.6B
Relative Value
The Relative Value of one
NOT
stock under the Base Case scenario is
123.24
EUR.
Compared to the current market price of 133.58 EUR,
Novartis AG
is
Overvalued by 8%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NOT
Relative Value
Base Case
123.24
EUR
Overvaluation 8%
Multiples Across Competitors
NOT Competitors Multiples
Novartis AG Competitors
Novartis AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
Novartis AG
DUS:NOT
|
232.9B EUR | 5.3 | 21.4 | 13.3 | 17 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
946.1B USD | 14.5 | 45.8 | 30.9 | 33 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.8B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
263.4B CHF | 4.3 | 20.4 | 12 | 13.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
225.3B GBP | 5.1 | 29.5 | 16.3 | 23 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 4.5 | 15.9 | 9.9 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD | 2.5 | 17.2 | 7.2 | 8.9 | |
| UK |
|
GSK plc
XETRA:GS71
|
97.1B EUR | 2.6 | 14.8 | 7.5 | 10.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
